Keywords: exelixis, s1p1, deal, bu, earn, 354m, california

Exelixis' S1P1 deal with BU could earn $354M

Article | 08 May 2009

California, USA-based Exelixis has established an exclusive, global collaboration with privately-held German drug major Boehringer Ingelheim, aiming to discover, develop ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Boehringer Ingelheim

Bristol-Myers Squibb

Go to company listing